Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
D412556-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $271.90 | |
D412556-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $728.90 |
Complement System Inhibitors
Synonyms | BDBM354268 | JM8C1SFX0U | CS-0068562 | DANICOPAN [JAN] | 1903768-17-1 | MLS006011963 | Danicopan free base | MS-30411 | (2S,4R)-1-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide | ACH44 |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Danicopan (ACH-4471, ACH-0144471, ACH-CFDIS, ALXN 2040) is a potent, selective and orally active inhibitor of factor D with Kd of 0.54 nM for human Factor D. Danicopan inhibits alternative pathway of complement (APC) activity, and has potential to block t |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Complement factor D inhibitor |
Product Description | Information Danicopan (ACH-4471) Danicopan (ACH-4471, ACH-0144471, ACH-CFDIS, ALXN 2040) is a potent, selective and orally active inhibitor of factor D with Kd of 0.54 nM for human Factor D. Danicopan inhibits alternative pathway of complement (APC) activity, and has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Targets alternative pathway of complement (APC) ; human Factor D (Cell-free assay) ; 0.54 nM(Kd) |
ALogP | 3.3 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|---|---|---|---|---|---|---|
Complement factor D inhibitor | INHIBITOR | ALA2176771 | Complement factor D | SINGLE PROTEIN | Homo sapiens | ||
Complement factor D inhibitor | INHIBITOR | ALA2176771 | Complement factor D | SINGLE PROTEIN | Homo sapiens |
IUPAC Name | (2S,4R)-1-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide |
---|---|
INCHI | InChI=1S/C26H23BrFN7O3/c1-14(36)25-19-8-16(17-10-29-15(2)30-11-17)6-7-20(19)35(33-25)13-24(37)34-12-18(28)9-21(34)26(38)32-23-5-3-4-22(27)31-23/h3-8,10-11,18,21H,9,12-13H2,1-2H3,(H,31,32,38)/t18-,21+/m1/s1 |
InChi Key | PIBARDGJJAGJAJ-NQIIRXRSSA-N |
Canonical SMILES | CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4CC(CC4C(=O)NC5=NC(=CC=C5)Br)F |
Isomeric SMILES | CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4C[C@@H](C[C@H]4C(=O)NC5=NC(=CC=C5)Br)F |
PubChem CID | 118323590 |
Molecular Weight | 580.41 |
Solubility | Solubility (25°C) In vitro DMSO: 100 mg/mL (172.29 mM); Water: Insoluble; Ethanol: Insoluble; |
---|
1. Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, Huang Y, Huang M, Brodsky RA. (2017) Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.. Haematologica, 102 (3): (466-475). [PMID:27810992] [10.1021/op500134e] |
2. Iyer A, Xu W, Reid RC, Fairlie DP. (2018) Chemical Approaches to Modulating Complement-Mediated Diseases.. J Med Chem, 61 (8): (3253-3276). [PMID:28977749] [10.1021/op500134e] |
3. Risitano AM, Kulasekararaj AG, Lee JW, Maciejewski JP, Notaro R, Brodsky R, Huang M, Geffner M, Browett P. (2021) Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica, 106 (12): (3188-3197). [PMID:33121236] [10.1021/op500134e] |
4. Wiles JA, Galvan MD, Podos SD, Geffner M, Huang M. (2020) Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471).. Curr Med Chem, 27 (25): (4165-4180). [PMID:31573880] [10.1021/op500134e] |